We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
VIVUS has reported on its recent meeting with the FDA regarding Testosterone MDTS (Metered Dose Transdermal Spray) for the treatment of Hypoactive Sexual Desire Disorder (HSDD).
CollaGenex Pharmaceuticals has initiated a Phase II, double-blinded, placebo-controlled, dose-finding clinical trial to evaluate the safety and efficacy of its novel compound, incyclinide (formerly known as COL-3), for the treatment of acne.
Biomira will delay the start of a late-stage clinical trial for its experimental cancer vaccine BLP25 until 2006 after discovering a manufacturing problem.
Newly-released Phase III data for vildagliptin, the first of a new class of oral antidiabetic drugs known as dipeptidyl peptidase-IV (DPP-IV) inhibitors, show the drug improves on currently available therapeutic options in several respects.
King Pharmaceuticals has reported that the FDA has accepted the company's supplemental new drug application seeking a new indication for Altace (ramipril).
Vernalis has signed a contract with Diosynth Biotechnology for process development, scale-up and manufacturing of V10153 for Phase III clinical trials.
Exelixis has initiated Phase I clinical trials to evaluate the safety, tolerability and pharmacokinetic profile of two anticancer compounds, XL844 and XL184.